No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers

PURPOSE: Lenalidomide, a weak substrate of P-glycoprotein (P-gp) in vitro, is an oral anticancer drug eliminated predominantly via renal excretion as unchanged compound. The role of P-gp in lenalidomide disposition and the associated clinical relevance were evaluated. METHODS: Two phase I, crossover...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Nianhang., Weiss, Daniel, Reyes, Josephine, Liu, Liangang, Kasserra, Claudia, Wang, Xiaomin, Zhou, Simon, Kumar, Gondi, Weiss, Lilia, Palmisano, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000408/
https://www.ncbi.nlm.nih.gov/pubmed/24659021
http://dx.doi.org/10.1007/s00280-014-2438-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4000408/
https://www.ncbi.nlm.nih.gov/pubmed/24659021
http://dx.doi.org/10.1007/s00280-014-2438-4

Ejemplares similares